These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 33760108)

  • 21. Narasin inhibits tumor metastasis and growth of ERα‑positive breast cancer cells by inactivation of the TGF‑β/SMAD3 and IL‑6/STAT3 signaling pathways.
    Chen J; Huang X; Li N; Liu B; Ma Z; Ling J; Yang W; Li T
    Mol Med Rep; 2020 Dec; 22(6):5113-5124. PubMed ID: 33174044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells.
    Zeng D; Liang YK; Xiao YS; Wei XL; Lin HY; Wu Y; Bai JW; Chen M; Zhang GJ
    Int J Cancer; 2020 Jul; 147(2):490-504. PubMed ID: 32020593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diallyl disulfide inhibits TGF‑β1‑induced upregulation of Rac1 and β‑catenin in epithelial‑mesenchymal transition and tumor growth of gastric cancer.
    Su B; Su J; Zeng Y; Ding E; Liu F; Tan T; Xia H; Wu YH; Zeng X; Ling H; Jiang H; Ai XH; Su Q
    Oncol Rep; 2018 Jun; 39(6):2797-2806. PubMed ID: 29620286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer.
    Arora R; Yates C; Gary BD; McClellan S; Tan M; Xi Y; Reed E; Piazza GA; Owen LB; Dean-Colomb W
    PLoS One; 2014; 9(6):e98370. PubMed ID: 24896091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple‑negative breast cancer cell lines.
    Gurdal H; Tuglu MM; Bostanabad SY; Dalkiliç B
    Int J Oncol; 2019 Apr; 54(4):1345-1356. PubMed ID: 30720056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
    Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
    J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.
    Madden JM; Mueller KL; Bollig-Fischer A; Stemmer P; Mattingly RR; Boerner JL
    Breast Cancer Res Treat; 2014 Sep; 147(2):283-93. PubMed ID: 25129346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
    Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
    Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
    Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
    J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor-like domain-containing protein 7 (EGFL7) enhances EGF receptor-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells.
    Luo BH; Xiong F; Wang JP; Li JH; Zhong M; Liu QL; Luo GQ; Yang XJ; Xiao N; Xie B; Xiao H; Liu RJ; Dong CS; Wang KS; Wen JF
    PLoS One; 2014; 9(6):e99922. PubMed ID: 24945379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells.
    Zuo Y; Xu H; Chen Z; Xiong F; Zhang B; Chen K; Jiang H; Luo C; Zhang H
    Oncol Rep; 2020 Jun; 43(6):1928-1944. PubMed ID: 32236631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis.
    Sinha S; Sharma S; Sharma A; Vora J; Shrivastava N
    Phytomedicine; 2021 Apr; 84():153492. PubMed ID: 33640782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
    El Guerrab A; Zegrour R; Nemlin CC; Vigier F; Cayre A; Penault-Llorca F; Rossignol F; Bignon YJ
    PLoS One; 2011; 6(9):e25080. PubMed ID: 21966417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AREG mediates the epithelial‑mesenchymal transition in pancreatic cancer cells via the EGFR/ERK/NF‑κB signalling pathway.
    Wang L; Wang L; Zhang H; Lu J; Zhang Z; Wu H; Liang Z
    Oncol Rep; 2020 May; 43(5):1558-1568. PubMed ID: 32323797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.
    Yang HL; Thiyagarajan V; Shen PC; Mathew DC; Lin KY; Liao JW; Hseu YC
    J Exp Clin Cancer Res; 2019 May; 38(1):186. PubMed ID: 31068208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
    Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
    Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel chalcone-based molecule, BDP inhibits MDA‑MB‑231 triple-negative breast cancer cell growth by suppressing Hsp90 function.
    Oh YJ; Seo YH
    Oncol Rep; 2017 Oct; 38(4):2343-2350. PubMed ID: 28849241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer.
    Srinivasan A; Thangavel C; Liu Y; Shoyele S; Den RB; Selvakumar P; Lakshmikuttyamma A
    Mol Carcinog; 2016 May; 55(5):743-56. PubMed ID: 25968914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
    Kim S; Lee J; Jeon M; Nam SJ; Lee JE
    Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.